AI Article Synopsis
- The study aimed to investigate the safety and effectiveness of belimumab in treating newly diagnosed systemic lupus erythematosus (SLE) patients.
- 30 patients underwent 6 months of belimumab treatment, showing significant improvements in various laboratory results and a reduction in disease activity.
- The findings suggest that belimumab is a safe and effective option for newly diagnosed SLE patients, potentially reducing the need for glucocorticoids and improving anemia with minimal side effects.
Article Abstract
Objective: To explore the therapeutic effectiveness and safety of belimumab in the treatment of recently diagnosed systemic lupus erythematosus (SLE).
Methods: Between January 2019 and February 2022, a total of 30 patients who had been recently diagnosed with SLE were selected for 6 months of belimumab treatment at the Department of Rheumatology and Immunology, Tianjin First Central Hospital. Laboratory test results and related adverse reactions were recorded at baseline and after treatment.
Results: Participants' white blood cell counts and complement 3, complement 4, and hemoglobin levels were higher after treatment than at baseline. Participants' immunoglobulin G and immunoglobulin M levels, SLE Disease Activity Index 2000 scores, glucocorticoid doses, erythrocyte sedimentation rates, and serum albumin/globulin ratios were lower after treatment. These differences were all statistically significant (p < .05).
Conclusion: Belimumab was safe and effective in patients recently diagnosed with SLE and might help to reduce the use of glucocorticoids and to improve anemia with few adverse reactions. Belimumab might be applied in the treatment of patients recently diagnosed with SLE with high disease activity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601783 | PMC |
| http://dx.doi.org/10.1002/iid3.716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ten tips in lupus nephritis management.
Clin Kidney J
January 2025
Division of Nephrology, School of Clinical Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR.
Lupus nephritis is an important cause of severe glomerulonephritis, and a leading cause of kidney failure in young adults. While the disease can lead to rapid destruction of nephrons if untreated, there are effective therapies to reverse the severe acute kidney injury and prevent the lifetime risk of kidney failure. Early diagnosis and timely intervention are therefore of critical importance.
View Article and Find Full Text PDFEffectiveness of Belimumab for Glucocorticoid Discontinuation in Juvenile-Onset Lupus Nephritis.
Indian J Nephrol
October 2024
Division of Pediatric Nephrology, Okinawa Prefectural Nanbu Medical Center, Children's Medical Center, Haebaru, Japan.
Lupus nephritis (LN) is an important complication of systemic lupus erythematosus, for which glucocorticoids (GCs) are the primary treatment. Due to the side effects associated with GCs, their long-term use should ideally be tapered and discontinued. At present, no such possibility exists without problematic flares after discontinuation.
View Article and Find Full Text PDFSystemic Lupus Erythematous: Gene Polymorphisms, Epigenetics, Environmental, Hormonal and Nutritional Factors in the Consideration of Personalized Therapy.
Arch Intern Med Res
December 2024
Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.
Systemic Lupus Erythematosus (SLE) is a chronic illness that can affect many tissues through the production of autoantibodies. A definite etiology has not been conclusively established, but current research points to the influences which include genetic, hormonal and environmental factors. SLE is difficult to treat due to its multifactorial pathogenesis and heterogeneity in clinical manifestations.
View Article and Find Full Text PDF[The clinical significance of resolvin D1 in patients with systemic lupus erythematosus treated with Belimumab].
Zhonghua Yi Xue Za Zhi
February 2025
Department of Rheumatology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
To explore the changes and significance of resolvin D1 (RvD1) in the treatment of systemic lupus erythematosus (SLE) with Belimumab. The clinical data from patients with moderate to severe disease activity SLE who received oral stable doses of glucocorticoids (≤10 mg/d) and/or immunosuppressants for more than 3 months at the outpatient or inpatient department of the First Affiliated Hospital of Soochow University from January 2022 to November, 2023 were retrospectively collected. All patients were treated with 10 mg/kg intravenous infusion of Belimumab.
View Article and Find Full Text PDFNew Treatment Regimens, New Drugs, and New Treatment Goals for Lupus Nephritis.
J Clin Med
January 2025
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus, affecting roughly 40% of all lupus patients. With the introduction of cyclophosphamide and mycophenolate mofetil, outcomes have dramatically improved. However, 10% of patients still progress towards end-stage kidney disease, which carries an elevated mortality rate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!